Imatinib-resistant PDGFR mutants don't bind imatinib

Stable Identifier
R-HSA-9674397
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

PDGFRA mutations that are resistant to imatinib include point mutations and small deletion mutations centered around residue D842 (Heinrich et al, 2003; Corless et al, 2005); the gatekeeper mutation T674I (Cools et al, 2003; Lierman et al, 2006; Simon et al, 2008; Heinrich et al, 2012; Evans et al, 2017; Smith et al, 2019); S601P (Salemi et al, 2009) and Y288C (Ip et al, 2019) (reviewed in Roskoski, 2018; Klug et al, 2018). The resistance of PDGFRA Y288C is not shown in this failed reaction.

Literature References
PubMed ID Title Journal Year
12660384 A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

Cools, J, Deangelo, DJ, Gotlib, J, Stover, EH, Legare, RD, Cortes, J, Kutok, J, Clark, J, Galinsky, I, Griffin, JD, Cross, NC, Tefferi, A, Malone, J, Alam, R, Schrier, SL, Schmid, J, Rose, M, Vandenberghe, P, Verhoef, G, Boogaerts, M, Wlodarska, I, Kantarjian, H, Marynen, P, Coutré, SE, Stone, R, Gilliland, DG

N. Engl. J. Med. 2003
29408302 The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders

Roskoski, R

Pharmacol. Res. 2018
12522257 PDGFRA activating mutations in gastrointestinal stromal tumors

Heinrich, MC, Corless, CL, Duensing, A, McGreevey, L, Chen, CJ, Joseph, N, Singer, S, Griffith, DJ, Haley, A, Town, A, Demetri, GD, Fletcher, CD, Fletcher, JA

Science 2003
18234315 Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia

Simon, D, Salemi, S, Yousefi, S, Simon, HU

J. Allergy Clin. Immunol. 2008
19210352 A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome

Salemi, S, Yousefi, S, Simon, D, Schmid, I, Moretti, L, Scapozza, L, Simon, HU

Allergy 2009
22665524 Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors

Heinrich, MC, Mariño-Enríquez, A, Presnell, A, Donsky, RS, Griffith, DJ, McKinley, A, Patterson, J, Taguchi, T, Liang, CW, Fletcher, JA

Mol. Cancer Ther. 2012
16645167 Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant

Lierman, E, Folens, C, Stover, EH, Mentens, N, Van Miegroet, H, Scheers, W, Boogaerts, M, Vandenberghe, P, Marynen, P, Cools, J

Blood 2006
29964125 Structural and clinical consequences of activation loop mutations in class III receptor tyrosine kinases

Klug, LR, Kent, JD, Heinrich, MC

Pharmacol. Ther. 2018
29093181 A precision therapy against cancers driven by KIT/PDGFRA mutations

Evans, EK, Gardino, AK, Kim, JL, Hodous, BL, Shutes, A, Davis, A, Zhu, XJ, Schmidt-Kittler, O, Wilson, D, Wilson, K, DiPietro, L, Zhang, Y, Brooijmans, N, LaBranche, TP, Wozniak, A, Gebreyohannes, YK, Schöffski, P, Heinrich, MC, Deangelo, DJ, Miller, S, Wolf, B, Kohl, N, Guzi, T, Lydon, N, Boral, A, Lengauer, C

Sci Transl Med 2017
15928335 PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

Corless, CL, Schroeder, A, Griffith, D, Town, A, McGreevey, L, Harrell, P, Shiraga, S, Bainbridge, T, Morich, J, Heinrich, MC

J. Clin. Oncol. 2005
31085175 Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Smith, BD, Kaufman, MD, Lu, WP, Gupta, A, Leary, CB, Wise, SC, Rutkoski, TJ, Ahn, YM, Al-Ani, G, Bulfer, SL, Caldwell, TM, Chun, L, Ensinger, CL, Hood, MM, McKinley, A, Patt, WC, Ruiz-Soto, R, Su, Y, Telikepalli, H, Town, A, Turner, BA, Vogeti, L, Vogeti, S, Yates, K, Janku, F, Abdul Razak, AR, Rosen, O, Heinrich, MC, Flynn, DL

Cancer Cell 2019
Participants
Participant Of
Normal reaction
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!